Ali Gholamrezanezhad1, Sahar Mirpour1, Jean-Francois H Geschwind2, Pramod Rao1, Romaric Loffroy1, Olivier Pellerin1, Eleni A Liapi1. 1. The Russell H. Morgan Department of Radiology and Radiological Science, Division of Interventional Radiology, The Johns Hopkins Hospital, Sheikh Zayed Tower, Suite 7203, 1800 Orleans Street, Baltimore, MD, 21287, USA. 2. Department of Radiology and Biomedical Imaging, Yale University School of Medicine, PO Box 208042, 330 Cedar Street, New Haven, CT, 06520, USA. jeff.geschwind@yale.edu.
Abstract
AIM: To evaluate the pharmacokinetic profile (PK) and embolization effect of 70-150-μm doxorubicin eluting beads (DEBs) following intra-arterial injection (i.a.) in the rabbit liver VX2 tumour model. MATERIALS AND METHODS: In this ACUC-approved study, 25 white New Zealand rabbits were randomly assigned into a small DEB group (SDB, n = 7, 70-150-μm DEBs), large DEB group (LDB, n = 7, 100-300-μm DEBs), untreated controls (n = 7), and doxorubicin controls (n = 4, without tumour, received i.a. 12.5 mg doxorubicin). Plasma PK was assessed up to 180 min post-injection. Drug tissue and liver enzyme levels, radiologic tumor response and histopathologic tumour necrosis were assessed at 7 days. RESULTS: Mean tumour doxorubicin concentrations were 922.83 nM (SD = 722.05) and 361.48 nM (SD = 473.23) for the SDB and LDB, respectively (p = 0.005). There was no statistically significant difference in tumour doxorubicinol, plasma doxorubicin and doxorubicinol PK values. More beads were observed in the SDB tumours (p = 0.01). Liver enzymes increased and gradually declined over the observation period, with significantly higher values in the SDB. CONCLUSION: In this preclinical study, plasma PK of i.a.-injected 70-150-μm DEBs was not different than that of 100-300-μm DEBs. More beads and higher tissue doxorubicin levels were observed in the SDB tumours. KEY POINTS: • Small and large doxorubicin-eluting beads show similar plasma pharmacokinetic profiles. • Higher tissue doxorubicin levels were observed in the small bead group. • Liver enzymes were overall significantly higher in the small bead group.
AIM: To evaluate the pharmacokinetic profile (PK) and embolization effect of 70-150-μm doxorubicin eluting beads (DEBs) following intra-arterial injection (i.a.) in the rabbit liver VX2 tumour model. MATERIALS AND METHODS: In this ACUC-approved study, 25 white New Zealand rabbits were randomly assigned into a small DEB group (SDB, n = 7, 70-150-μm DEBs), large DEB group (LDB, n = 7, 100-300-μm DEBs), untreated controls (n = 7), and doxorubicin controls (n = 4, without tumour, received i.a. 12.5 mg doxorubicin). Plasma PK was assessed up to 180 min post-injection. Drug tissue and liver enzyme levels, radiologic tumor response and histopathologic tumour necrosis were assessed at 7 days. RESULTS: Mean tumourdoxorubicin concentrations were 922.83 nM (SD = 722.05) and 361.48 nM (SD = 473.23) for the SDB and LDB, respectively (p = 0.005). There was no statistically significant difference in tumourdoxorubicinol, plasma doxorubicin and doxorubicinol PK values. More beads were observed in the SDB tumours (p = 0.01). Liver enzymes increased and gradually declined over the observation period, with significantly higher values in the SDB. CONCLUSION: In this preclinical study, plasma PK of i.a.-injected 70-150-μm DEBs was not different than that of 100-300-μm DEBs. More beads and higher tissue doxorubicin levels were observed in the SDB tumours. KEY POINTS: • Small and large doxorubicin-eluting beads show similar plasma pharmacokinetic profiles. • Higher tissue doxorubicin levels were observed in the small bead group. • Liver enzymes were overall significantly higher in the small bead group.
Authors: Marta Burrel; María Reig; Alejandro Forner; Marta Barrufet; Carlos Rodríguez de Lope; Silvia Tremosini; Carmen Ayuso; Josep M Llovet; María Isabel Real; Jordi Bruix Journal: J Hepatol Date: 2012-02-05 Impact factor: 25.083
Authors: Julien Namur; Steven J Citron; Marty T Sellers; Mark H Dupuis; Michel Wassef; Michel Manfait; Alexandre Laurent Journal: J Hepatol Date: 2011-05-18 Impact factor: 25.083
Authors: Matthew R Dreher; Karun V Sharma; David L Woods; Goutham Reddy; Yiqing Tang; William F Pritchard; Oscar A Chiesa; John W Karanian; Juan A Esparza; Danielle Donahue; Elliot B Levy; Sean L Willis; Andrew L Lewis; Bradford J Wood Journal: J Vasc Interv Radiol Date: 2011-12-16 Impact factor: 3.464
Authors: M Victoria Gonzalez; Yiqing Tang; Gary J Phillips; Andrew W Lloyd; Brenda Hall; Peter W Stratford; Andrew L Lewis Journal: J Mater Sci Mater Med Date: 2007-07-25 Impact factor: 3.896
Authors: R Golfieri; E Giampalma; M Renzulli; R Cioni; I Bargellini; C Bartolozzi; A D Breatta; G Gandini; R Nani; D Gasparini; A Cucchetti; L Bolondi; F Trevisani Journal: Br J Cancer Date: 2014-06-17 Impact factor: 7.640
Authors: William F Pritchard; David L Woods; Juan A Esparza-Trujillo; Matthew F Starost; Michal Mauda-Havakuk; Andrew S Mikhail; Ivane Bakhutashvili; Shelby Leonard; Elizabeth C Jones; Venkatesh Krishnasamy; John W Karanian; Bradford J Wood Journal: J Vasc Interv Radiol Date: 2020-02-24 Impact factor: 3.464
Authors: Andrew S Mikhail; Elliot B Levy; Venkatesh P Krishnasamy; David L Woods; Juan A Esparza-Trujillo; Ivane Bakhutashvili; Filip Banovac; Paul G Wakim; Ayele H Negussie; Yiqing Tang; Alexander Henman; Sean L Willis; John W Karanian; William F Pritchard; Andrew L Lewis; Bradford J Wood Journal: Cardiovasc Intervent Radiol Date: 2020-08-16 Impact factor: 2.740